Risk factors
Replimune Group (REPL) risk factors
Item 1A of every Replimune Group, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2026 10-K risk factors57 risks7 new7 dropped11 reworded
RP1’s resubmitted BLA faces unresolved FDA concerns and potential advisory committee scrutiny in late July 2026.
Filed Jun 29, 2026 - FY2025 10-K risk factors57 risks
Replimune is entirely dependent on developing and commercializing its lead oncolytic immunotherapy candidate RP1 and proprietary RPx platform. The company faces high capital requirements, relying on $483.8 million in cash reserves at March 31, 2025. Internal manufacturing operations rely on a single 63,000 square foot facility in Framingham, Massachusetts.
Filed May 22, 2025